Novo Nordisk is investing DKK800 million (£90.7m) to upgrade and expand facilities at its Kalundborg production plant in Denmark.
The facilities currently manufacture around half of the world’s insulin and will be rebuilt and expanded to allow for future production of a range of diabetes treatments.
Established in 1969, the site covers a total area of 1,200,000 sqm and employs more than 3,000 people.
The company has invested more than DKK16 billion (£1.8bn) in the Kalundborg site since 2000. From here the company
The projects are expected to be completed in 2022.